🇺🇸 Tango Therapeutics, Inc.TNGX
Get Tango Therapeutics, Inc. filings on Telegram the moment they are published.
Follow Tango Therapeutics, Inc. on TelegramOne tap starts your 30-day free trial. No card needed.
Subject: 8-K Items 7.01, 8.01, 9.01
Overview: Announced Phase 1/2 study results for vopimetostat and daraxonrasib in pancreatic cancer, showing an 82% objective response rate and a planned Phase 3 trial in 1H 2027.
Source: SEC EDGAR · Original filing
Get filings like this in Telegram the moment they are published — for the companies you follow.
Start 30-day trial About Finterest